Serum-Free Stem Cell Differentiation with Kinase Inhibitors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for differentiating human embryonic stem cells (hES) into cardiomyocytes are poorly defined and rely on serum-containing media, leading to batch variations and the use of xenoproducts, making them unsuitable for clinical applications.

Innovation Solution

A defined serum-free medium comprising specific factors such as prostaglandin I2 (PGI2) and p38 MAP kinase inhibitors like SB203580 is used to induce cardiomyocyte differentiation, eliminating the need for xenoproducts and enhancing the reproducibility of cardiomyocyte formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If serum-containing medium is used for cardiomyocyte differentiation, then differentiation can be achieved, but batch-to-batch variations and undefined composition reduce reliability

Engineering Contradiction:

Improvereproducibility of cardiomyocyte differentiationVSAvoidcomposition consistency of differentiation medium

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The invention extracts and eliminates serum components from the differentiation medium, replacing them with defined small molecules (prostaglandin I2 and p38 MAP kinase inhibitors). This removal of the problematic serum component while maintaining differentiation capability directly resolves the contradiction between achieving differentiation and ensuring composition consistency.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the chemical parameters of the differentiation medium by substituting complex serum proteins with specific small molecules at controlled concentrations. This parameter change transforms the medium from an undefined serum-based system to a defined small-molecule system, improving both reliability and composition stability.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If xenoproducts are used in differentiation medium, then cardiomyocyte formation can be enhanced, but clinical applicability is compromised

Engineering Contradiction:

Improveefficiency of cardiomyocyte formationVSAvoidpresence of xenoproducts

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and removes xenoproducts (animal-derived serum components) from the differentiation medium, replacing them with synthetic small molecules. This elimination maintains cardiomyocyte formation efficiency while removing harmful foreign components, enabling clinical applicability.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention replaces complex, potentially contaminated serum products with simple, synthetic small molecules that can be produced without animal sources. These small molecules serve as disposable, defined components that eliminate xenoproduct concerns while maintaining differentiation efficiency.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Ease of manufacture

If spontaneous differentiation in serum medium is used, then cardiomyocytes can be generated, but the process lacks definition and control

Engineering Contradiction:

Improvesimplicity of differentiation processVSAvoiddefinition of differentiation protocol

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The invention changes the key parameters of the differentiation medium by defining specific small molecule concentrations (prostaglandin I2 and p38 MAP kinase inhibitors) instead of using variable serum compositions. This creates a precise, controllable protocol while maintaining ease of manufacture through a straightforward medium formulation.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for efficient and reproducible differentiation of hES cells into cardiomyocytes without xenoproducts, making them suitable for clinical use and cardiac tissue repair.

Implementation Method 1

Differentiation of pluripotent stem cells with a kinase inhibitor or PGI2

Methodology Applied

Scientific EffectProstaglandin signaling:

Implementation Method 2

Differentiation of pluripotent stem cells with a kinase inhibitor or PGI2

Methodology Applied

Scientific EffectKinase inhibition:

Data Source

PatentUS9422521B2Differentiation of pluripotent stem cells with a kinase inhibitor or PGI2

Publication Date: 2016.08.23 ES CELL INT

AI summary

The present invention provides a process of differentiating stem cells, in particular hES cells, into cardiomyocytes and into neural progenitors by growing the hES cells in the presence of a defined medium that is substantially free of xeno- and serum-components and thus comprises a clinically compliant medium. The defined media comprises defined factors that contribute to the promotion of differentiation to cardiomyocytes and neural progenitors. The invention also includes defined culture media and cell populations and methods of using them.